Zai Lab Limited (ZLAB) Monday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310 for the treatment of extensive-stage small cell lung cancer (ES-SCLC).
ZL-1310, currently being evaluated in a Phase 1a/1b study, had previously received an Orphan Drug designation for SCLC.
"This designation reinforces the clinical progress we have achieved for ZL-1310 to-date, and we remain on track to initiate a pivotal study in small cell lung cancer later this year, positioning us for a potential accelerated approval in 2027," said Rafael G. Amado, President, Head of Global Research and Development, Zai Lab.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.